SCHEMBL1715294

SCHEMBL1715294

CC(=O)NCCCCCCN1CCN(CCCOc2ccc(C(=N)N)cc2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 4/20 0.50
PRMT1 Q99873 3/20 0.50
F2 P00734 2/20 0.50
ST14 Q9Y5Y6 2/20 0.50
TMPRSS2 O15393 2/20 0.50
PLAU P00749 1/20 0.50
PRMT5 O14744 1/20 0.50
SLC22A2 O15244 1/20 0.50
SLC22A1 O15245 1/20 0.50
PTP4A3 O75365 1/20 0.50
SLC22A3 O75751 1/20 0.50
F10 P00742 1/20 0.50
PLG P00747 1/20 0.50
S100B P04271 1/20 0.50
CHRM2 P08172 1/20 0.50
CHRM4 P08173 1/20 0.50
CHRM5 P08912 1/20 0.50
ADRA2A P08913 1/20 0.50
CYP2D6 P10635 1/20 0.50
AOC1 P19801 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1714559 0.83 PRSS1 (0.69) HRH3PRMT1F2ST14TMPRSS2
SCHEMBL1714612 0.82 HRH3 (0.60) HRH3HRH2HRH1DRD2DRD4
Hydrochloric Acid SCHEMBL1714997 0.82 PRSS1 (0.70) HRH3PRMT1F2ST14TMPRSS2
SCHEMBL14367475 0.81 PRMT1 (0.60) HRH3PRMT1F2ST14TMPRSS2
SCHEMBL14367429 0.80 PRSS1 (0.65) HRH3PRMT1F2ST14TMPRSS2
Hydrochloric Acid SCHEMBL1714774 0.80 PRSS1 (0.61) HRH3PRMT1F2ST14TMPRSS2
SCHEMBL14367437 0.79 PRSS1 (0.63) HRH3PRMT1F2ST14TMPRSS2
Hydrochloric Acid SCHEMBL1714831 0.79 PRSS1 (0.66) HRH3PRMT1F2ST14TMPRSS2
SCHEMBL14367421 0.79 PRSS1 (0.63) HRH3PRMT1F2ST14TMPRSS2
SCHEMBL14367511 0.79 PRMT1 (0.57) HRH3PRMT1F2ST14TMPRSS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1481966-B1 NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO LTD (JP) 2011-07-20 EP disclosed
US-7291617-B2 Arylamidine derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2007-11-06 US disclosed
US-7291617-B2 Arylamidine derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2007-11-06 US disclosed
US-7291617-B2 Arylamidine derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2007-11-06 US disclosed
US-20050113424-A1 Novel arylamidine derivative or salt thereof TOYAMA CHEMICAL CO., LTD (JP) 2005-05-26 US disclosed
EP-1481966-A1 NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2004-12-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113424-A1 Novel arylamidine derivative or salt thereof SLC7A1, NAT1, NACA HRH3 395/4885PRMT1 740/4885F2 4338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.